Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s00280-016-3231-3
Published Online: 2017-01-31
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shimizu, Toshio
Yonesaka, Kimio
Hayashi, Hidetoshi
Iwasa, Tsutomu
Haratani, Koji
Yamada, Hironori
Ohwada, Shoichi
Kamiyama, Emi
Nakagawa, Kazuhiko
License valid from 2017-01-31